Sugi Predict

Sugi Predict / Compounds / Ethylhydrocupreine

Ethylhydrocupreine

Ethylhydrocupreine

SCHEMBL467210

CCOc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@@]3C[C@@H]4CC)c2c1

nearest known ligand 0.89

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 12/20 0.89
▸ KDM4E B2RXH2 6/20 0.89
▸ ALDH1A1 P00352 5/20 0.89
▸ HSD17B10 Q99714 5/20 0.89
▸ ADRA2A P08913 4/20 0.89
▸ SLC6A4 P31645 4/20 0.89
▸ OPRM1 P35372 4/20 0.89
▸ KCNH2 Q12809 4/20 0.89
▸ HPGD P15428 3/20 0.89
▸ CYP3A4 P08684 3/20 0.89
▸ TSHR P16473 2/20 0.89
▸ MEN1 O00255 2/20 0.89
▸ KMT2A Q03164 2/20 0.89
▸ SLC6A3 Q01959 2/20 0.89
▸ CHRM2 P08172 1/20 0.89
▸ SCN1A P35498 4/20 0.86
▸ SCN2A Q99250 4/20 0.86
▸ SCN3A Q9NY46 4/20 0.86
▸ SLC22A1 O15245 3/20 0.66
▸ ABCB11 O95342 3/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylhydrocupreine SCHEMBL29361889 1.00 CYP2D6 (0.89) CYP2D6KDM4EALDH1A1HSD17B10ADRA2A
Ethylhydrocupreine SCHEMBL3866393 0.99 CYP2D6 (0.88) CYP2D6KDM4EALDH1A1HSD17B10ADRA2A
Ethylhydrocupreine SCHEMBL31285607 0.99 CYP2D6 (0.88) CYP2D6KDM4EALDH1A1HSD17B10ADRA2A
Hydroquinidine SCHEMBL25429352 0.94 CYP2D6 (1.00) CYP2D6KDM4EALDH1A1HSD17B10ADRA2A
Hydroquinidine SCHEMBL109602 0.94 CYP2D6 (1.00) CYP2D6KDM4EALDH1A1HSD17B10ADRA2A
Hydroquinidine SCHEMBL308963 0.94 CYP2D6 (1.00) CYP2D6KDM4EALDH1A1HSD17B10ADRA2A
Hydroquinidine SCHEMBL25429627 0.94 CYP2D6 (1.00) CYP2D6KDM4EALDH1A1HSD17B10ADRA2A
Hydroquinidine SCHEMBL23509584 0.94 CYP2D6 (1.00) CYP2D6KDM4EALDH1A1HSD17B10ADRA2A
Hydroquinidine SCHEMBL22754576 0.94 CYP2D6 (1.00) CYP2D6KDM4EALDH1A1HSD17B10ADRA2A
Hydroquinidine SCHEMBL22754573 0.94 CYP2D6 (1.00) CYP2D6KDM4EALDH1A1HSD17B10ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021054927-A2 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS SOUTH DAKOTA BOARD OF REGENTS (US) 2021-03-25 — — WO claimed
EP-3263145-B1 ANTIMICROBIAL COMPOSITIONS AND METHODS FOR LOCKING CATHETERS BECTON DICKINSON CO (US) 2021-01-20 — — EP claimed
US-20200048305-A1 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS SOUTH DAKOTA BOARD OF REGENTS (US) 2020-02-13 — — US claimed
US-9872941-B2 Antimicrobial compositions and methods for locking catheters BECTON, DICKINSON AND COMPANY (US) 2018-01-23 — — US claimed
EP-3263145-A1 ANTIMICROBIAL COMPOSITIONS AND METHODS FOR LOCKING CATHETERS Becton, Dickinson and Company (US) 2018-01-03 — — EP claimed
EP-1998825-B1 ANTIMICROBIAL COMPOSITIONS AND METHODS FOR LOCKING CATHETERS BECTON DICKINSON CO (US) 2017-10-18 — — EP claimed
US-20170216493-A1 Antimicrobial Compositions and Methods for Locking Catheters BECTON, DICKINSON AND COMPANY 2017-08-03 — — US claimed
US-9649411-B2 Antimicrobial compositions and methods for locking catheters BECTON, DICKINSON AND COMPANY (US) 2017-05-16 — — US claimed
US-9622969-B2 Polymer conjugated protein micelles SOUTH DAKOTA STATE UNIV (US) 2017-04-18 — — US claimed
US-20160213818-A1 Antimicrobial Compositions and Methods for Locking Catheters BECTON, DICKINSON AND COMPANY 2016-07-28 — — US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007100776-A2 ANTIMICROBIAL COMPOSITIONS AND METHODS FOR LOCKING CATHETERS BECTON, DICKINSON AND COMPANY (US) 2007-09-07 — — WO claimed
US-20070202177-A1 Antimicrobial Compositions and Methods for Locking Catheters BECTON, DICKINSON AND COMPANY (US) 2007-08-30 — — US claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 — — CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 — — EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 — — WO claimed
WO-1995016711-A9 ANTIBODIES AGAINST PNEUMOLYSINE AND THEIR APPLICATIONS — 1995-08-03 — — WO claimed
WO-1995016711-A1 ANTIBODIES AGAINST PNEUMOLYSINE AND THEIR APPLICATIONS UNIVERSIDAD DE OVIEDO (ES) 1995-06-22 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048305-A1 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS GSTK1, GSTO1, GSTM2 CYP2D6 2387/4885KDM4E 4520/4885ALDH1A1 2491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.